This may be obtained using high-affinity leptin-binding molecules (analogously to the soluble TNFα receptors used to treat RA) or by blocking the leptin receptor with monoclonal humanized antibodies or mutant leptins, which are able to bind to this receptor without activating it [7]. Here, LEPR is linked to rheumatoid arthritis.